- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04380610
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
200 pediatric and 200 adult SCA participants will undergo mGFR using iohexol at baseline and at one year. On the same day, participants will undergo clinical and laboratory variables important for developing an eGFR equation. From baseline data, the investigators will perform a training and validation cohort of biologically relevant predictor variables to develop a novel equation. Then the investigators will compare the novel SCA eGFR equation to the established eGFR equation. From one year data, the investigators will determine the longitudinal concordance between pediatric and adult novel and standard eGFR equations with mGFR and variables that may alter longitudinal inferences.
In a subset of 30 adult participants, the investigators will also evaluate the correlation between mGFR using iohexol and a novel measure of mGFR that is more time efficient
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jeffrey Lebensburger, DO, MSPH
- Phone Number: 205 638-9285
- Email: jlebensburger@peds.uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35223
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Jeffrey D Lebensburger, DO
- Phone Number: 205-638-9285
- Email: jlebensburger@peds.uab.edu
-
Principal Investigator:
- Julie Kanter Washko, MD
-
Principal Investigator:
- Jeffrey Lebensburger, DO, MSPH
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois Chicage
-
Contact:
- Santosh Saraf, MD, BS
-
-
Tennessee
-
Memphis, Tennessee, United States, 38163
- Recruiting
- University of Tennessee Health Science Center
-
Contact:
- Kenneth Ataga, MBBS
-
Memphis, Tennessee, United States, 38106
- Recruiting
- St Jude Childrens Research Hospital
-
Contact:
- Jane Hankins, MD, MS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- SCA patients (HbSS and SB0 thalassemia)
- Age: 5.0-50.0 at enrollment
Exclusion Criteria:
- Recent SCA complication associated with hospitalization (within 30 days) or ED visit (within 14 days)
- Current AKI defined as >0.3mg/g increase in SCr from prior visit
- Known history of anaphylaxis with contrast agent or known pregnancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pediatric SCA
We will develop a novel eGFR equation in 200 pediatric participants
|
We will perform mGFR in 400 SCA patients
|
Adult SCA
We will develop a novel eGFR equation in 200 adult participants
|
We will perform mGFR in 400 SCA patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To develop a novel SCA-specific eGFR equation and compare with existing eGFR equations validated for the general population
Time Frame: 5 years
|
The investigators will use biologically relevant variables to develop a new equation for eGFR in pediatric and adult sickle cell patients
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the longitudinal concordance between pediatric and adult novel and standard eGFR equations with mGFR and variables that may alter longitudinal inferences.
Time Frame: 5 years
|
To compare the concordance between eGFR and mGFR from baseline to one year
|
5 years
|
To test the correlation of the novel mGFR method using VFI FAST and iohexol mGFR.
Time Frame: 5 years
|
To perform a 3 hour mGFR and compare this mGFR to the 6 hour mGFR (iohexol)
|
5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jeffrey Lebensburger, DO, MSPH, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R01HL153386 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on iohexol GFR
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI); Health Resources and Services...CompletedKidney Transplantation | Kidney Failure | Kidney DonationUnited States
-
Ligand PharmaceuticalsCyDex Pharmaceuticals, Inc.Withdrawn
-
Association d' Utilisation du Rein Artificiel SANTERecruitingKidney Function IssueFrance
-
CyDex Pharmaceuticals, Inc.Syneos Health; Ligand PharmaceuticalsCompletedContrast-induced Nephropathy | Coronary AngiographyCanada
-
Taipei Medical University HospitalCompletedRenal Insufficiency | MoralityTaiwan
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompleted
-
Assiut UniversityUnknownCKD | GIT - Gastrointestinal Tract Hemorrhage
-
Genzyme, a Sanofi CompanyTerminatedFabry DiseaseAustria, Brazil, France, United States, Argentina, Belgium, Canada, Finland, Hungary, Norway, Poland, Spain, Taiwan, United Kingdom
-
Nova Scotia Health AuthorityCompletedContrast Media DosingCanada
-
University Hospital, ToursCompleted